Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.

Belfius Equities Global Health Care C Cap

Ranked 7 out of 19 in - Pharmaceuticals & Health Care over 12 months
All calculations are in EUR unless stated

Objective

The fund invests mainly in stocks from the Health Care sector (medical equipment, pharmaceuticals, biotechnology, etc.) listed on the exchanges of the three major regions (Asia, Europe, and America).

Showing fund performance in Belgium View performance globally

Performance

Pharmaceuticals & Health Care over : 31/03/2017 - 31/03/2018

Total Return

Quarterly Performance

to 31/03/2018 Annual Q1 Q2 Q3 Q4
2018 -4.3%
2017 5.7% 6.4% 1.8% -0.8% -1.6%
2016 -5.4% -12.1% 8.1% -0.7% 0.2%
2015 17.8% 21.6% -2.3% -9.7% 9.8%
2014 33.7% 4.6% 5.4% 12.0% 8.3%
2013 29.6% 17.9% 0.9% 2.3% 6.4%
2012 13.2% 5.0% 4.7% 4.9% -1.8%
2011 9.3% -1.5% 5.1% -5.5% 11.8%
2010 9.2% 7.4% -3.0% 0.4% 4.4%
2009 15.6% -4.5% 4.2% 7.1% 8.4%
2008 -19.4% -16.8% -1.0% 8.9% -10.0%
2007 -10.0% -0.5% 0.0% -4.4% -5.4%
2006 1.0% 1.0% -5.7% 7.5% -1.4%
2005 22.8% 2.6% 11.9% 3.7% 3.1%
2004 -2.7% 1.8% 2.9% -4.6% -2.7%
2003 -0.1% -4.9% 6.8% -2.4% 0.7%
2002 -31.4% 0.7% -22.9% -9.3% -2.6%
2001 -9.5% -8.8% 5.5% -7.2% 1.4%
2000 39.3% 9.5% 16.6% 10.2% -0.9%
1999 6.4% 9.1% -2.3% -8.7% 9.4%

Month by Month Performance

Returns Vs Risk

Registered For Sale In

  1. Austria
  2. Belgium
  3. France
  4. Germany
  5. Luxembourg

Fund Info

  • Launch date04/06/1997
  • Share Class size310Mn
  • Base currencyUSD
  • ISIN BE0163900674

Purchase Info

  • Min. initial investment1
  • Min. regular additional investment0

Charges

  • Annual management1.50%
  • Initial investment1.5

Related News

Pfizer power play: healthcare stars react to $14bn deal

Citywire Selector canvassed sector specialists on what the pharma giant’s latest purchase means for M&A and long-term investments.

Analyst watch: Candriam boosts biotech team

Healthcare specialist Rudi Van den Eynde set to be assisted in drug development knowledge in biotechnology space.

Pfizer & Allergan's abandoned mega-merger: what happens next

As pharmaceutical giant halts its merger with Allergan, Citywire Selector asked if the sector had cracked its M&A addiction.

Biotech star’s team bolstered with new hire

Candriam Investors Group appoints senior analyst to join Citywire A-rated manager's specialist healthcare team.

Pfizer to snap up Allergan: star managers clash over major deal

Leading sector specialists offer divided views on the benefits of the $160bn merger, which marks the biggest tie-up in the sector's history.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).